All Stories

  1. Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

    Article • Journal of Medical Economics, April 2019, Taylor & Francis

    Dr Zhong Yuan, veronica ashton

  2. A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban

    Article • Current Medical Research and Opinion, July 2017, Taylor & Francis

    Dr Zhong Yuan

  3. Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives

    Article • Current Medical Research and Opinion, June 2014, Informa Healthcare

    Dr Zhong Yuan

  4. Rivaroxaban benefit:risk in hip and knee replacement

    Article • Vascular Health and Risk Management, March 2014, Taylor & Francis

    Dr Peter M DiBattiste, Dr Zhong Yuan, Dr Richard Joel Friedman